Ensysce Bioscience News Today

Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical ...

25.04.2024 - ~ Dr. Kirkpatrick Leads the Companys Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (Ensysce or the Company), a clinical stage ... Seite 1

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) and Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability. Valuation & Earnings This table compares Abeona […]

Ensysce Biosciences (NASDAQ:ENSC – Free Report) had its target price lowered by HC Wainwright from $9.00 to $7.00 in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Ensysce Biosciences’ Q3 2023 earnings at ($0.93) EPS, Q4 […]

Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) and GH Research (NASDAQ:GHRS – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Valuation and Earnings This table compares Ensysce Biosciences […]

Ensysce Biosciences, Inc. (NASDAQ:ENSC – Free Report) – Analysts at HC Wainwright issued their Q2 2023 earnings estimates for shares of Ensysce Biosciences in a research note issued on Monday, July 3rd. HC Wainwright analyst B. Pachaiyappan forecasts that the company will post earnings of ($1.23) per share for the quarter. HC Wainwright currently has […]

HC Wainwright reiterated their buy rating on shares of Ensysce Biosciences (NASDAQ:ENSC – Free Report) in a research note issued to investors on Monday morning, MarketBeat.com reports. HC Wainwright also issued estimates for Ensysce Biosciences’ Q2 2023 earnings at ($1.23) EPS, Q3 2023 earnings at ($0.91) EPS, Q4 2023 earnings at ($0.70) EPS, FY2023 earnings […]

<iframe src=https://www.youtube.com/embed/E5Z-MqXkTOI></iframe>Ensysce Bioscience CEO Dr Lynn Kirkpatrick joined Steve Darling from Proactive to share more details about the company that... | June 15, 2023

Ensysce Bioscience CEO Dr. Lynn Kirkpatrick joined Steve Darling from Proactive to share more details about the company that has proprietary technology...

Ensysce Biosciences, Inc. (OTCMKTS:ENSC – Get Rating) – Equities research analysts at Zacks Investment Research dropped their Q3 2022 earnings per share (EPS) estimates for Ensysce Biosciences in a research note issued on Tuesday, May 17th. Zacks Investment Research analyst B. Sorensen now expects that the company will earn ($0.22) per share for the quarter, […]